Immunotherapies for cancer and infectious diseases
Transgene (Euronext: TNG), part of Institut Mérieux, is a publicly traded French biotechnology company focused on discovering and developing immune-targeted therapies for the treatment of cancers and infectious diseases.
Transgene (Euronext: TNG), part of Institut Mérieux, is a publicly traded French biotechnology company focused on discovering and developing immune-targeted therapies for the treatment of cancers and infectious diseases.
Latest News
- May 24, 2018 - Transgene Announces Upcoming Investor Meetings
- May 23, 2018 - Combined General Meeting of May 23, 2018
- May 17, 2018 - Transgene to Present New Clinical Data on Oncolytic Virus Pexa-Vec at ASCO 2018
- May 2, 2018 - Availability of Preparatory Documents for the Combined General Meeting (Ordinary and Extraordinary Sessions) of May 23, 2018
